Ralitza Martin, MD
Pulmonary Disease · Atlanta, GANPI 1306011739
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Intuitive Surgical at 41.0% of the total. Reporting peaked in 2022 at $18,423 and has fallen 54.8% since, to $8,322 in 2025. Among pulmonary disease clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $316.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$19K
- Pulmonx Corporation$18K
- Cook Incorporated$8K
- Johnson & Johnson$154
- AstraZeneca$149
- Cook Medical LLC$122
- plus $892 from 25 others
What the payments were for
- Consulting fees$14,90031%
- Speaking & faculty fees$22,86848%
- Travel & lodging$4,80710%
- Food & beverage$4,89910%
- Education$280%
- Gifts$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 67 | $19,473 |
| Pulmonx Corporation | 28 | $18,381 |
| Cook Incorporated | 2 | $8,368 |
| Johnson & Johnson(2 entities) | 2 | $154 |
| AstraZeneca | 2 | $149 |
| Cook Medical LLC | 3 | $122 |
| GSK | 6 | $101 |
| Pfizer | 5 | $78 |
| Insmed, Inc. | 3 | $77 |
| Novartis | 2 | $52 |
| Boehringer Ingelheim | 3 | $50 |
| Mallinckrodt Enterprises LLC | 2 | $49 |
| Philips North America LLC | 2 | $46 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| ZOLL Medical Corporation | 1 | $33 |
| Mylan Specialty L.p. | 2 | $31 |
| Healthmyne, Inc. | 1 | $30 |
| Olympus America Inc. | 2 | $30 |
| Ambu Inc. | 1 | $28 |
| CSL Behring | 1 | $28 |
| Lilly USA, LLC | 1 | $25 |
| Advanced Respiratory, Inc | 2 | $23 |
| Viatris Specialty LLC | 1 | $21 |
| Merck | 1 | $20 |
| Sanofi | 1 | $19 |
| Bayer | 1 | $18 |
| Grifols USA, LLC | 1 | $16 |
| Gilead | 1 | $15 |
| Abbott | 1 | $15 |
| Resmed Corp | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPHYR ENDOBRONCHIAL VALVE$14,640
- Da Vinci Surgical System$11,447
- DA VINCI SP$6,650
- Blue Rhino$4,500
- Melker$3,868
- Pulmonx Endobronchial Valve EBV$3,352
- CHARTIS CATHETER$2,423
- ZEPHYR DELIVERY CATHETER$2,423
- PULMONX CHARTIS TABLET CONSOLE$2,423
- RYBREVANT$141
- IMFINZI$131
How this compares
$47,540 in reported general payments places this provider in the 90th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $153,730 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,153 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C | $16 | $153,73013 claims |
| Boehringer IngelheimSpiriva Respimat | $50 | $6,15312 claims |
| GSKBreo Ellipta | $101 | $4,36211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Atlanta
- Colin SwensonAtlanta$255K
- Eric FlenaughAtlanta$93K
- Gregory MartinAtlanta$88K
- Victor TsengAtlanta$55K
- Venkatesh LakshminarayananAtlanta$33K
- Sisir AkkineniAtlanta$21K
- Gerald StatonAtlanta$21K
- Mirza AliAtlanta$16K
- Srihari VeeraraghavanAtlanta$16K
- Lawrence McDermottSavannah$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.